- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: SCH-420814 | SCH420814
Compound class: Synthetic organic
Comment: Preladenant (SCH 420814) was an adenosine A2A receptor antagonist being developed for Parkinson's disease. Promising Phase 2 trial results did not translate to a significant effect over placebo in Phase 3 trial. Development has been discontinued.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Factor SA, Wolski K, Togasaki DM, Huyck S, Cantillon M, Ho TW, Hauser RA, Pourcher E. (2013)
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease.
Mov. Disord., 28 (6): 817-20. [PMID:23589371]
2. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K. (2011)
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
Lancet Neurol, 10 (3): 221-9. [PMID:21315654]
3. Müller CE, Ferré S. (2007)
Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders.
Recent Pat CNS Drug Discov, 2 (1): 1-21. [PMID:18221214]
4. Szabó N, Kincses ZT, Vécsei L. (2011)
Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.
Expert Opin Drug Metab Toxicol, 7 (4): 441-55. [PMID:21332415]